<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sica, Domenic A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Meta-Analyses of ARBs to Elucidate Link to Cancer, MI, and Dementia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">This article provides an update on controversies surrounding angiotensin receptor blockers (ARBs). Eight different ARBs are currently available, all with variable pharmacological properties. However, when considering a class effect, what applies to one drug may not necessarily pertain to all drugs in the class.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>